Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 24, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - July 24, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

7/24/17 - "Method and System for Managing Patient Healthcare Prognosis" in Patent Application Approval Process (USPTO 20170193165)
By a News Reporter-Staff News Editor at Clinical Trials Week A patent application by the inventors Mandalika, Sastry Subbaraya; Bharadwaj, Palash, filed on December 30, 2016, was made available online on July 13, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been ass
7/24/17 - "Method of Preparing a Pharmaceutical Composition" in Patent Application Approval Process (USPTO 20170189329)
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors STEIN, STEPHEN W.; SCHULTZ, DAVID W.; SIMONS, JOHN K.; HANSEN, WILLIAM F., filed on July 28, 2015, was made available online on July 13, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent appli
7/24/17 - "Pharmaceutical Compositions for the Treatment of Helicobacter Pylori" in Patent Application Approval Process (USPTO 20170189341)
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors Fathi, Reza; Raday, Gilead; Goldberg, Guy; Gosselin, Patrick, filed on March 22, 2017, was made available online on July 13, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has n
7/24/17 - "Ultrasound Shear Wave Elastography Featuring Therapy Monitoring" in Patent Application Approval Process (USPTO 20170188997)
By a News Reporter-Staff News Editor at Clinical Trials Week A patent application by the inventors Xie, Hua; Zhou, Shiwei; Robert, Jean-luc; Shamdasani, Vijay Thakur; Huang, Sheng-Wen, filed on June 15, 2015, was made available online on July 13, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This p
7/24/17 - Abbott Laboratories Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jul. 6, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Abbott Laboratories was posted on July 6, 2017. The SEC file number is 0001179110-17-010183.. A U.S. Securities and Exchange Commission filing is a f
7/24/17 - Abbott Laboratories Files SEC Form 8-K, Current Report (Jul. 7, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Abbott Laboratories was posted on July 7, 2017. The SEC file number is 0001104659-17-044080.. A U.S. Securities and Exchange Commission filing is a f
7/24/17 - Acceleron Pharma Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jul. 7, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acceleron Pharma Inc. was posted on July 7, 2017. The SEC file number is 0001179110-17-010224.. A U.S. Securities and Exchange Commission filing is a
7/24/17 - Acceleron Pharma Inc. Files SEC Form SC 13G/A, Statement of Acquisition of Beneficial Ownership By Individuals (Jul. 10, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acceleron Pharma Inc. was posted on July 10, 2017. The SEC file number is 0000215457-17-003421.. A U.S. Securities and Exchange Commission filing is
7/24/17 - Additional funding to develop a drug for Alzheimer's disease
By a News Reporter-Staff News Editor at Pharma Business Week E-Scape Bio announced an extension of its Series A funding to a total of $63 million. Created as a spin-off from research conducted at the Gladstone Institutes, E-Scape Bio is a biopharmaceutical company with a mission to develop new therapies to treat neurodegenerative disorders such a
7/24/17 - Aeterna Zentaris names new CEO and considers options for the firm [Oman News Agency]
The share price of Canada- based Aeterna Zentaris had shot up by nearly 200% to $3.01 by Friday lunchtime compared to Tuesdays close, with the company considering what to do following some good news. This news was the acceptance by the US Food and Drug Administration of the companys New Drug Application seeking approval of Macrilen for the evaluati
7/24/17 - Agios Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jul. 6, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Agios Pharmaceuticals Inc. was posted on July 6, 2017. The SEC file number is 0001209191-17-044054.. A U.S. Securities and Exchange Commission filing
7/24/17 - Alexion to Report Second Quarter 2017 Results and Strategic Update on Thursday, July 27, 2017
By a News Reporter-Staff News Editor at Pharma Business Week Alexion Pharmaceuticals, Inc. announced that the Company will report its financial results for the second quarter 2017 on Thursday, July 27, 2017 before the US financial markets open. Following the release of the financial results, Alexion management will conduct a conference call and a
7/24/17 - Alimera Sciences Inc. Files SEC Form 8-K, Current Report (Jul. 10, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Alimera Sciences Inc. was posted on July 10, 2017. The SEC file number is 0001267602-17-000052.. A U.S. Securities and Exchange Commission filing is
7/24/17 - Allergan Reports New Data Reinforcing the Effectiveness of Viberzi Eluxadoline to Treat the Symptoms Associated with Irritable Bowel Syndrome with...
By a News Reporter-Staff News Editor at Gastroenterology Week Allergan plc announced additional results of a prespecified prospective pooled subgroup analysis from the two Phase 3 studies, which evaluated the efficacy and safety of Viberzi in nearly 2,500 IBS-D patients, of whom 36 percent reported use of loperamide in the 12 months prior to stud
7/24/17 - Allurion Technologies Raises $27 Million in Series C Funding to Take Weight Loss Product Mainstream
By a News Reporter-Staff News Editor at Clinical Trials Week Allurion Technologies, makers of the Elipse Balloon- the world's first and only procedureless gastric balloon for weight loss- announced that it has secured $27 million in Series C funding. The round was led by existing investor Romulus Capital, with participation from Cogepa Investm
7/24/17 - Alnylam Pharmaceuticals, Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jul. 11, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Alnylam Pharmaceuticals, Inc. was posted on July 11, 2017. The SEC file number is 0001553878-17-000042.. A U.S. Securities and Exchange Commission fi
7/24/17 - AMAG Pharmaceuticals Launches Intrarosa? (prasterone) in the U.S. a Novel Product to Treat Moderate to Severe Dyspareunia Due to Menopause
AMAG Pharmaceuticals, Inc. today announced the commercial availability of Intrarosa? at pharmacies nationwide, supported by a newly created 137- person women s health sales force. Intrarosa is the first and only FDA- approved, local non-estrogen product for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atro
7/24/17 - Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin bevacizumab
By a News Reporter-Staff News Editor at Biotech Business Week Amgen and Allergan plc. announced that the Companies will discuss data supporting the ABP 215 Biologics License Application with the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration. ABP 215 is a biosimilar candidate to Avastin and is the first bevacizumab
7/24/17 - Amgen And QB3@953 Announce Winners Of The Amgen Golden Ticket
By a News Reporter-Staff News Editor at Pharma Business Week Amgen and QB3@ 953 announced that Darmiyan and Enable Biosciences have won the Amgen Golden Ticket at QB3@ 953. "Early detection and disease monitoring are critical in both the research and clinical settings," said David Reese, M.D., senior vice president Translational Sciences at Amge
7/24/17 - Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS Carfilzomib Label
By a News Reporter-Staff News Editor at Biotech Business Week Amgen announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and a variation to the marketing application to the European Medicines Agency to include overall survival data from the Phase 3 head-to-head ENDEAVOR trial in the product info
7/24/17 - Amicus Therapeutics Inc. Files SEC Form 8-K, Current Report (Jul. 11, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Amicus Therapeutics Inc. was posted on July 11, 2017. The SEC file number is 0001104659-17-044385.. A U.S. Securities and Exchange Commission filing
7/24/17 - Amphastar Announces Jury Verdict in Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc.
Amphastar Pharmaceuticals, Inc. announced today that a federal jury delivered a unanimous verdict in favor of Amphastar in a lawsuit brought by Momenta Pharmaceuticals, Inc. and Sandoz Inc. in the U.S. Court for the District of Massachusetts. The jury found the claims of Momenta s U.S. Patent No. 7,575,886 to be invalid for lack of enablement
7/24/17 - Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Files An 8-K Other Events
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Files An 8-K Other EventsITEM 8.01.Other Events. On July 24, 2017, Amphastar Pharmaceuticals, Inc. (Amphastar) announced in a press release that a federal jury delivered a unanimous verdict in favor of the Company in a lawsuit brought by Momenta Pharmaceuticals, Inc. and Sandoz Inc. in the U.S. Co
7/24/17 - Amphastar Pharmaceuticals, Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jul. 7, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Amphastar Pharmaceuticals, Inc. was posted on July 7, 2017. The SEC file number is 0001209191-17-044410.. A U.S. Securities and Exchange Commission f
7/24/17 - Ampio Pharmaceuticals, Inc. Files SEC Form 8-K, Current Report (Jul. 7, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Ampio Pharmaceuticals, Inc. was posted on July 7, 2017. The SEC file number is 0001193125-17-223744.. A U.S. Securities and Exchange Commission filin
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415